diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5360diaendo-5360Research ArticleСтатьиArticlesНовые возможности в достижении компенсации углеводного обмена при сахарном диабете 2 типа: янувия - ингибитор дипептидилпептидазы IV типаNovye vozmozhnosti v dostizhenii kompensatsii uglevodnogo obmena pri sakharnom diabete 2 tipa: yanuviya - ingibitor dipeptidilpeptidazy IV tipaБалаболкинМихаил ИвановичBalabolkinMikhail Ivanovich-КлебановаЕлена МихайловнаKlebanovaElena Michailovna-ГОУ ВПО ММА им. И.М. Сеченова200815092008113№3 (2008)4348Copyright © Балаболкин М.И., Клебанова Е.М., 20082008Балаболкин М.И., Клебанова Е.М.Balabolkin M.I., Klebanova E.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5360

Янувия является первым препаратом нового класса ингибиторов ДПП-4, обладает высокой эффективностью, которая сравнима с эффектом препаратов сульфонилмочевины, применяемых для терапии СД 2. Прием янувии хорошо переносится больными, а частота развития гипогликемии идентична той, которая встречается у больных, получавших плацебо. Влияние янувии на снижение апоптоза бета-клеток и их неогенез сопровождается увеличением количества бета-клеток островков поджелудочной железы, что может замедлить или даже остановить прогрессирование СД 2 и его поздних осложнений.

ситаглиптинЯнувиясахарный диабет 2 типаReferencesDiabetes Control and complications trial research group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus // Arch Ophthalmol - 1995 - Vol. 113 - P. 36-51.Diabetes Control and complications trial research group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus // Arch Ophthalmol - 1995 - Vol. 113 - P. 36-51.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment of risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - Vol. 352. - P. 837-853.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment of risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - Vol. 352. - P. 837-853.UK Prospective Diabetes Study (UKPDS) Group. Effects of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. - 1998. - Vol. 352. - P. 854-865.UK Prospective Diabetes Study (UKPDS) Group. Effects of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. - 1998. - Vol. 352. - P. 854-865.World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complication- Part 1: Diagnosis and classification of diabetes mellitus, Geneva: WHO, 1999.World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complication- Part 1: Diagnosis and classification of diabetes mellitus, Geneva: WHO, 1999.American Diabetes Association. Standards of medical care in diabetes // Diabetes Care - 2007 - Vol. 30 - Suppl.1, S1-S-103.American Diabetes Association. Standards of medical care in diabetes // Diabetes Care - 2007 - Vol. 30 - Suppl.1, S1-S-103.European Diabetes Policy Group. A desktop guide to type 2 diabetes // Diabet Med - 1999 - Vol. 16 - P. 716-730.European Diabetes Policy Group. A desktop guide to type 2 diabetes // Diabet Med - 1999 - Vol. 16 - P. 716-730.American Association of clinical endocrinologist. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management-2002 update // Endocr Pract - 2002 - Vol. 8 - Suppl. 1 - P. 40-82.American Association of clinical endocrinologist. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management-2002 update // Endocr Pract - 2002 - Vol. 8 - Suppl. 1 - P. 40-82.Canadian Diabetes Association. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada // Can J Diabetes - 2003 - Vol. 27 - Suppl.2 - P. S1-S152.Canadian Diabetes Association. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada // Can J Diabetes - 2003 - Vol. 27 - Suppl.2 - P. S1-S152.Nathan D.M., Buse J.B., Davidson M.B. et al., Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy // Diabetologia - 2006 - Vol. 49 - P. 1711-1721.Nathan D.M., Buse J.B., Davidson M.B. et al., Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy // Diabetologia - 2006 - Vol. 49 - P. 1711-1721.Drucker D.J: The biology of incretin hormones. // Cell Metab. - 2006. - vol. 3. - P.153-165.Drucker D.J: The biology of incretin hormones. // Cell Metab. - 2006. - vol. 3. - P.153-165.Deacon C. F, Carr R. D, Holst J. J. DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. // Frontiers in Bioscience. - 2008. - vol. 13. - P. 1780-1794.Deacon C. F, Carr R. D, Holst J. J. DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. // Frontiers in Bioscience. - 2008. - vol. 13. - P. 1780-1794.Nauck M.A, M.M. Heimesaat, C. Orskov, J.J. Holst, R. Ebert & W. Creutzfeldt. Preserved incretin activity of glucagon-like peptide 1 [7-3 6 amide] but not of synthetic human gastric inhibitor polypeptide in patients with type-2 diabetes. // J Clin Invest. - 1993. - vol . 91. - P. 301-307.Nauck M.A, M.M. Heimesaat, C. Orskov, J.J. Holst, R. Ebert & W. Creutzfeldt. Preserved incretin activity of glucagon-like peptide 1 [7-3 6 amide] but not of synthetic human gastric inhibitor polypeptide in patients with type-2 diabetes. // J Clin Invest. - 1993. - vol . 91. - P. 301-307.Vilsboll T, T. Krarup, S. Madsbad & J.J. Holst. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. // Regul Pept. - 2003. - vol. 114. - P. 115-121.Vilsboll T, T. Krarup, S. Madsbad & J.J. Holst. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. // Regul Pept. - 2003. - vol. 114. - P. 115-121.Nauck M, F. Stockmann, R. Ebert & W. Creutzfeldt: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. // Diabetologia 29, 46-52 (1986).Nauck M, F. Stockmann, R. Ebert & W. Creutzfeldt: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. // Diabetologia 29, 46-52 (1986).Toft-Nielsen M.B, M.B. Damholt, S. Madsbad, L.M. Hilsted, T.E.Hughes, B.K. Michelsen & J.J. Holst: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. // J Clin Endocrinol Metab 86, 3717-3723 (2001).Toft-Nielsen M.B, M.B. Damholt, S. Madsbad, L.M. Hilsted, T.E.Hughes, B.K. Michelsen & J.J. Holst: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. // J Clin Endocrinol Metab 86, 3717-3723 (2001).Vilsboll T, T. Krarup, C.F. Deacon, S. Madsbad & J.J. Holst: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. // Diabetes 50, 609-613 (2001).Vilsboll T, T. Krarup, C.F. Deacon, S. Madsbad & J.J. Holst: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. // Diabetes 50, 609-613 (2001).Kjems L.L, J.J. Holst, A. Volund & S. Madsbad: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. // Diabetes 52, 380-386 (2003).Kjems L.L, J.J. Holst, A. Volund & S. Madsbad: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. // Diabetes 52, 380-386 (2003).Vilsboll T, F.K. Knop, T. Krarup, A. Johansen, S. Madsbad, S. Larsen, T. Hansen, O. Pedersen & J.J. Holst: The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. // J Clin Endocrinol Metab 88, 4897-4903 (2003).Vilsboll T, F.K. Knop, T. Krarup, A. Johansen, S. Madsbad, S. Larsen, T. Hansen, O. Pedersen & J.J. Holst: The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. // J Clin Endocrinol Metab 88, 4897-4903 (2003).Herman G.A., Stevens C., Van Dyck K. et al., Pharmacokinetics and pharmacodynamics of sitagliptin, aninhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomised, double-blind, placebo controlled studies with single oral doses // Clin Pharmacol Ther - 2005 - Vol. 78 - P. 675-688.Herman G.A., Stevens C., Van Dyck K. et al., Pharmacokinetics and pharmacodynamics of sitagliptin, aninhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomised, double-blind, placebo controlled studies with single oral doses // Clin Pharmacol Ther - 2005 - Vol. 78 - P. 675-688.Bergman A.J., Stevens C., Zhou Y.Y. et al., Pharmacokinetic and pharmacodynamic properties of mulpiple oral doses of sitagliptin, adipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers // Clin Ther - 2006 - Vol. 28 - P. 55-72.Bergman A.J., Stevens C., Zhou Y.Y. et al., Pharmacokinetic and pharmacodynamic properties of mulpiple oral doses of sitagliptin, adipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers // Clin Ther - 2006 - Vol. 28 - P. 55-72.Herman G.A., Bergman A., Liu F. et al., Pharmacokinetic and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects // J Clin Pharmacol - 2006 - V0l. 46 - P. 876-886Herman G.A., Bergman A., Liu F. et al., Pharmacokinetic and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects // J Clin Pharmacol - 2006 - V0l. 46 - P. 876-886Herman G.A., Bergman A., Stevens C. et al., Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes // J Clin Endocrinol Metab - 2006 - Vol. 91- P. 4612-4619.Herman G.A., Bergman A., Stevens C. et al., Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes // J Clin Endocrinol Metab - 2006 - Vol. 91- P. 4612-4619.Herman G., Hanefeld M., Wu M. et al., Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor on glycaemic control after 12 weeks in patients with type 2 diabetes // Diabetes - 2005 - Vol.54 - Suppl. 1 - A134 - P. 541.Herman G., Hanefeld M., Wu M. et al., Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor on glycaemic control after 12 weeks in patients with type 2 diabetes // Diabetes - 2005 - Vol.54 - Suppl. 1 - A134 - P. 541.Scott R. Herman G., Zhao P. et al., Twelve week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor in the treatment of type 2 diabetes // Diabetes - 2005 - Vol. 54 - Suppl. 1 - A10, 41-OR.Scott R. Herman G., Zhao P. et al., Twelve week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor in the treatment of type 2 diabetes // Diabetes - 2005 - Vol. 54 - Suppl. 1 - A10, 41-OR.Aschner P., Kipnes M.S., Lunceford J.K. et al., Sitagliptin study 021 group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycaemic control in patients with type 2 diabetes // Diabetes Care - 2006 - Vol. 29 - P. 2632-2637.Aschner P., Kipnes M.S., Lunceford J.K. et al., Sitagliptin study 021 group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycaemic control in patients with type 2 diabetes // Diabetes Care - 2006 - Vol. 29 - P. 2632-2637.Brazg R., Thomas K., Zhao P. et al., Effect of adding MK-0431 to ongoing metformin therapy in type 2 diabetic patients who have inadequate glycemic control on metformin // Diabetes - 2005 - Vol. 54 - Suppl. 1 - P.A3 - 11-OR.Brazg R., Thomas K., Zhao P. et al., Effect of adding MK-0431 to ongoing metformin therapy in type 2 diabetic patients who have inadequate glycemic control on metformin // Diabetes - 2005 - Vol. 54 - Suppl. 1 - P.A3 - 11-OR.Williams-Herman D, Johnson J, Lunceford J. Initial combination therapy with sitagliptin and metformin provides effective and durable glycemic control over 1 year in patients with type 2 diabetes: a pivotal phase III clinical trial. // Poster presented at: the American Diabetes Association 67th Annual Scientific Sessions; June 22-26, 2007; Chicago, Illinois, USA.Williams-Herman D, Johnson J, Lunceford J. Initial combination therapy with sitagliptin and metformin provides effective and durable glycemic control over 1 year in patients with type 2 diabetes: a pivotal phase III clinical trial. // Poster presented at: the American Diabetes Association 67th Annual Scientific Sessions; June 22-26, 2007; Chicago, Illinois, USA.Nauck M, Meininger G, Sheng D, et al, for the 024 Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared to the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, doubleblind, non-inferiority trial. Diabetes Obes Metab. 9, 194-205 (2007)Nauck M, Meininger G, Sheng D, et al, for the 024 Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared to the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, doubleblind, non-inferiority trial. Diabetes Obes Metab. 9, 194-205 (2007)

The authors declare that there are no conflicts of interest present.